Latest news with #ImmunoPreciseAntibodies
Business Wire
21-05-2025
- Business
- Business Wire
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audiences. 'This collaboration with CORE IR represents an important step in IPA's ongoing commitment to improving our communication with the investment community and increasing market visibility,' said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. 'As we continue to execute on our growth strategy and expand our global capabilities, we believe CORE IR's expertise will help us better articulate our value proposition to existing and prospective shareholders.' Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, investor outreach, and support for IPA's communication programs. 'We are excited to work alongside the team at IPA,' said Scott Gordon, Co-Founder and President of CORE IR. 'IPA has established itself as a pioneering force in the antibody discovery and development space. We look forward to helping the company increase its engagement with the broader investment community.' About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). For more information, visit About CORE IR CORE IR is a strategic communications firm specializing in investor and public relations services. The firm supports public and private companies across a wide range of industries with customized programs to enhance corporate visibility, engage stakeholders, and support business objectives.
Yahoo
21-05-2025
- Business
- Yahoo
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
AUSTIN, Texas, May 21, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audiences. "This collaboration with CORE IR represents an important step in IPA's ongoing commitment to improving our communication with the investment community and increasing market visibility," said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. "As we continue to execute on our growth strategy and expand our global capabilities, we believe CORE IR's expertise will help us better articulate our value proposition to existing and prospective shareholders." Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, investor outreach, and support for IPA's communication programs. "We are excited to work alongside the team at IPA," said Scott Gordon, Co-Founder and President of CORE IR. "IPA has established itself as a pioneering force in the antibody discovery and development space. We look forward to helping the company increase its engagement with the broader investment community." About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family"). For more information, visit About CORE IR CORE IR is a strategic communications firm specializing in investor and public relations services. The firm supports public and private companies across a wide range of industries with customized programs to enhance corporate visibility, engage stakeholders, and support business objectives. View source version on Contacts Investor Relations Louie Toma, CPA, CFAManaging Director investors@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Barnama
28-04-2025
- Business
- Barnama
Carterra Kicks Off 2025 Symposia Series On Advancing Drug Discovery
KUALA LUMPUR, April 28 (Bernama) -- Carterra Inc, a provider of innovative technologies, is partnering with ImmunoPrecise Antibodies (IPA), ACROBiosystems, and Curia to host its 2025 symposia series titled 'Unlocking High-Throughput Biology in Drug Discovery'. The series will feature four one-day events across key cities in the United States (US) and Europe, including Boston on May 6, Munich on June 4, Cambridge on June 6, and San Francisco on June 24. 'Past attendees of Carterra's symposia have shared their enthusiasm, highlighting the wide variety of presentations as well as the collaborative, open environment as reasons to attend. We are looking forward to record attendance and premium content again this year,' said its Vice President of Marketing and Product, Chris Silva in a statement.
Barnama
25-04-2025
- Business
- Barnama
Carterra Announces its 2025 Symposia Series on Speeding Drug Discovery with AI/ML and Other New Technologies
SALT LAKE CITY, April 25 (Bernama) -- Carterra Inc., the world leader in enabling high-throughput biology, is partnering with co-hosts ImmunoPrecise Antibodies (IPA), ACROBiosystems, and Curia to offer its 2025 symposia series titled, 'Unlocking High-Throughput Biology in Drug Discovery.' The series will feature four, one-day events across key cities in the U.S. and Europe. The event locations and dates are as follows: May 6, 2025: Boston, Massachusetts, USA June 4, 2025: Munich, Germany June 6, 2025: Cambridge, United Kingdom June 24, 2025: San Francisco, California, USA The symposia are tailored for the drug discovery scientist. Topics will cover antibody and large molecule through small molecule discovery, including cutting-edge areas such as machine learning and AI approaches for protein engineering, emerging oncology targets, engineering of bispecific and multifunctional antibodies, library generation, biophysical characterization, and high-definition epitope binning to enable novel biotherapeutics, among others.
